Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
JAMA ; 327(18): 1782-1794, 2022 05 10.
Artículo en Inglés | MEDLINE | ID: mdl-35510397

RESUMEN

Importance: In nonurban areas with limited access to thrombectomy-capable centers, optimal prehospital transport strategies in patients with suspected large-vessel occlusion stroke are unknown. Objective: To determine whether, in nonurban areas, direct transport to a thrombectomy-capable center is beneficial compared with transport to the closest local stroke center. Design, Setting, and Participants: Multicenter, population-based, cluster-randomized trial including 1401 patients with suspected acute large-vessel occlusion stroke attended by emergency medical services in areas where the closest local stroke center was not capable of performing thrombectomy in Catalonia, Spain, between March 2017 and June 2020. The date of final follow-up was September 2020. Interventions: Transportation to a thrombectomy-capable center (n = 688) or the closest local stroke center (n = 713). Main Outcomes and Measures: The primary outcome was disability at 90 days based on the modified Rankin Scale (mRS; scores range from 0 [no symptoms] to 6 [death]) in the target population of patients with ischemic stroke. There were 11 secondary outcomes, including rate of intravenous tissue plasminogen activator administration and thrombectomy in the target population and 90-day mortality in the safety population of all randomized patients. Results: Enrollment was halted for futility following a second interim analysis. The 1401 enrolled patients were included in the safety analysis, of whom 1369 (98%) consented to participate and were included in the as-randomized analysis (56% men; median age, 75 [IQR, 65-83] years; median National Institutes of Health Stroke Scale score, 17 [IQR, 11-21]); 949 (69%) comprised the target ischemic stroke population included in the primary analysis. For the primary outcome in the target population, median mRS score was 3 (IQR, 2-5) vs 3 (IQR, 2-5) (adjusted common odds ratio [OR], 1.03; 95% CI, 0.82-1.29). Of 11 reported secondary outcomes, 8 showed no significant difference. Compared with patients first transported to local stroke centers, patients directly transported to thrombectomy-capable centers had significantly lower odds of receiving intravenous tissue plasminogen activator (in the target population, 229/482 [47.5%] vs 282/467 [60.4%]; OR, 0.59; 95% CI, 0.45-0.76) and significantly higher odds of receiving thrombectomy (in the target population, 235/482 [48.8%] vs 184/467 [39.4%]; OR, 1.46; 95% CI, 1.13-1.89). Mortality at 90 days in the safety population was not significantly different between groups (188/688 [27.3%] vs 194/713 [27.2%]; adjusted hazard ratio, 0.97; 95% CI, 0.79-1.18). Conclusions and Relevance: In nonurban areas in Catalonia, Spain, there was no significant difference in 90-day neurological outcomes between transportation to a local stroke center vs a thrombectomy-capable referral center in patients with suspected large-vessel occlusion stroke. These findings require replication in other settings. Trial Registration: ClinicalTrials.gov Identifier: NCT02795962.


Asunto(s)
Arteriopatías Oclusivas , Procedimientos Endovasculares , Accidente Cerebrovascular Isquémico , Trombectomía , Activador de Tejido Plasminógeno , Anciano , Anciano de 80 o más Años , Arteriopatías Oclusivas/complicaciones , Arteriopatías Oclusivas/tratamiento farmacológico , Arteriopatías Oclusivas/cirugía , Isquemia Encefálica/tratamiento farmacológico , Isquemia Encefálica/etiología , Isquemia Encefálica/cirugía , Femenino , Instituciones de Salud , Humanos , Accidente Cerebrovascular Isquémico/tratamiento farmacológico , Accidente Cerebrovascular Isquémico/etiología , Accidente Cerebrovascular Isquémico/cirugía , Masculino , España , Accidente Cerebrovascular/tratamiento farmacológico , Accidente Cerebrovascular/etiología , Accidente Cerebrovascular/cirugía , Trombectomía/efectos adversos , Activador de Tejido Plasminógeno/administración & dosificación , Activador de Tejido Plasminógeno/efectos adversos , Resultado del Tratamiento , Población Urbana
2.
Rev. neurol. (Ed. impr.) ; 66(10): 340-343, 16 mayo, 2018. ilus
Artículo en Español | IBECS (España) | ID: ibc-173460

RESUMEN

Introducción. La panarteritis nodosa es una vasculitis necrotizante que afecta de manera predominante a arterias de pequeño y mediano calibre de la piel y los órganos internos. La afectación neurológica sucede en un 25% de casos: los ictus isquémicos son relativamente frecuentes, pero las lesiones hemorrágicas resultan extremadamente raras. La hemorragia subaracnoidea es una expresión poco común de la enfermedad, asociada la inmensa mayoría de las veces a patología aneurismática. En nuestro conocimiento, sólo existe otro caso descrito de panarteritis nodosa con hemorragia subaracnoidea en la edad pediátrica sin patología aneurismática subyacente. Caso clínico. Niña de 7 años que presentó una hemorragia subaracnoidea no aneurismática con extensión intraparenquimatosa a los ganglios basales izquierdos. Previamente se había diagnosticado panarteritis nodosa y enfermedad protrombótica, en tratamiento con fármacos inmunodepresores y antiagregantes en ese momento. Conclusiones. Las características clínicas de la panarteritis nodosa, junto con el tratamiento antiagregante para prevenir la enfermedad tromboembólica en nuestra paciente, podrían haber predispuesto al evento hemorrágico en el proceso de la vasculitis cerebral. El manejo estándar de la hemorragia subaracnoidea es necesario en estos casos debido a que los aneurismas cerebrales son la causa más común de hemorragia subaracnoidea en un contexto de panarteritis nodosa


Introduction. Polyarteritis nodosa is a necrotizing vasculitis that mainly affects small and medium-sized arteries in skin and internal organs. Neurological involvement is reported in around 25% of cases: ischemic stroke is relatively common, but haemorrhagic lesions are extremely rare. Subarachnoid haemorrhage in polyarteritis nodosa is an uncommon expression of this disease, mostly associated with aneurism rupture. To the best of the authors’ knowledge, there is just one published case in pediatric age with polyarteritis nodosa and subarachnoid haemorrhage with no underlying aneurismal disease. Case report. A 7-year-old girl, who presented a non-aneurismal subarachnoid haemorrhage with intraparenchymal extension in the left basal ganglia. She was previously diagnosed with polyarteritis nodosa and prothrombotic condition, being under immunosuppressive and anti-platelet treatment at that moment. Conclusions. The clinical features of polyarteritis nodosa together with continued anti-platelet therapy to prevent thromboembolic disease in this patient could have predisposed to the haemorrhagic event in the process of cerebral vasculitis. Standard subarachnoid haemorrhage management is initially required in such cases as cerebral aneurysms are the most common cause of haemorrhage in the context of polyarteritis nodosa disease


Asunto(s)
Humanos , Femenino , Niño , Hemorragia Subaracnoidea/diagnóstico por imagen , Vasculitis/diagnóstico por imagen , Hidrocefalia/diagnóstico por imagen , Lesiones Encefálicas/diagnóstico por imagen , Vasculitis/complicaciones , Trastornos de la Conciencia/complicaciones , Hidrocefalia/terapia , Angiografía , Hemorragia Subaracnoidea/terapia , Lesiones Encefálicas/complicaciones , Lesiones Encefálicas/terapia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA